250 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
to comply with and operate under our deferred prosecution agreement (DPA) with the U.S. Department of Justice; potential liability for intellectual
8-K
EX-99.1
wk6skr8sfp5did632me
31 Jan 24
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
6jx d388u5nr7u
8 Nov 23
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
7:01am
8-K
EX-99.1
5zm jl85afrgdjh
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
50pf8sk 48134
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
o2qa9g7wepszm07sppb
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
ymvrg3odvtpde7noxpg
2 Aug 23
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
0zag2ones
10 May 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
0qqu99a1owoi31
3 Nov 22
Key financial highlights and outlook
7:00am